Overview
Mynd Therapeutics develops next-generation psychedelic-derived compounds targeting treatment-resistant depression and PTSD through precision neurochemistry.
More in Neuropharmaceuticals
Latest industry news
Synchron Halts BCI Trials After Device Falls Short of Performance Benchmarks
2026-11-14 · Industry
China's Brain-Computer Interface Sector Enters Clinical Reality With First Commercial Implants
2026-11-13 · Industry
Synchron Pauses Brain Implant Trials After Performance Issues Surface
2026-11-12 · Industry
Generative AI Is Closing the Gap on Brain-Computer Interface Accuracy and Resolution
2026-11-11 · Research
Company details
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →